Doubleblind study with the novel antidepressant viloxazine versus imipramine in 50 in-patients
Floru, L.; Czarny, G.; Tegeler, J.
Arzneimittel-Forschung 26(6): 1170-1171
1976
ISSN/ISBN: 0004-4172 PMID: 786314 Document Number: 103444
In this double-blind study on 50 depressive patients viloxazine in dosages between 150-300 mg/die, showed to be a very active and well tolerated thymoleptic substance. Its profile of activity seems similar to that of imipramine. The differences in favour of viloxazine were: a more rapid onset of its effect, a more balanced stimulation of energetical level versus clearing up to depressed mood, evident better results in patients aged over 50, fewer drop-outs on account of complications (especially confusional states or psychotic symptom provocations) and fewer side-effects such as vegetative disfunction, vertigo, and weight increase. More initial fatigue reactions, slight sleep disturbances and 3 hypertensive transient reactions must be emphasized on the side of viloxazine.